Nadine Beauger becomes the new Chief Executive Officer of the Institute for Research in Immunology and Cancer — Commercialization of Research (IRICoR). She is taking over the role from Michel Bouvier who remains Chief Executive Officer of the Institute for Research in Immunology and Cancer (IRIC) at Université de Montréal (UdeM). Nadine Beauger was nominated at the latest meeting of the Assembly of Members of IRICoR, on the recommendation of the Board of Directors.
Prior to this appointment, Nadine Beauger served as Vice President – Scientific Liaison (intellectual property, academia-industry relations). She has been working at IRICoR since 2009 and has a proven track record in technology assessment and transfer, venture capital, intellectual property (IP), due diligence, and clinical and biotechnological research with thorough experience in both the private and the academic sectors. At IRICoR, Nadine Beauger was in charge of identifying commercially promising projects and increasing the value of projects from the IRICoR’s portfolio for commercialization. She was instrumental in the development and management of nearly 40 patent families, which have led to eight successful current licensing agreements with private partners (an investment of close to $35 million from the private sector).
“We are positive that Nadine Beauger’s experience and expertise will be tremendous assets to the successful completion of IRICoR’s projects,” says Johanne Boucher Champagne, Chair of the Board of Directors of IRICoR. “Her diligent management and enthusiasm are essential qualities to carry the mission of our organization, which is why she can count on the support of the entire Board of Directors.”
“The Board extends its thanks to Michel Bouvier for all the work he accomplished leading IRICoR over the last four years,” adds Mrs. Boucher Champagne. “Under his leadership, IRICoR has become a key player in academic-based drug discovery and now enjoys an international prestige, which translates into considerable socio-economic and scientific benefits.”
Nadine Beauger holds a Ph.D. in Biomedical Sciences (Hematology and Oncology) and a M.Sc. in Cellular Biopathology from Université de Montréal, as well as a B.Sc. in Anatomy from McGill University. She also holds an MBA degree from HEC Montréal and is a member of the Association of University Transfer Managers (AUTM).
About the Institute for Research in Immunology and Cancer — Commercialization of Research
The Institute for Research in Immunology and Cancer — Commercialization of Research (IRICoR) is a not-for-profit drug discovery and commercialization centre based at the Université de Montréal (UdeM). IRICoR’s main objective is to accelerate the discovery, development and commercialization of innovative therapies originating from the Institute for Research in Immunology and Cancer (IRIC), other scientific research units at UdeM, and external partners. IRICoR invests in highly innovative projets to rapidly translate academic research into commercialization and identifies the best developing partners for commercially promising projects. Projects supported by IRICoR gain access to the drug discovery infrastructures if IRIC and professionals from the pharmaceutical industry. For more information: www.iricor.ca.
À propos de l’Institut de recherche en immunologie et en cancérologie
Pôle de recherche et centre de formation ultramoderne, l’Institut de recherche en immunologie et en cancérologie (IRIC) de l’Université de Montréal a été créé en 2003 pour élucider les mécanismes du cancer et accélérer la découverte de nouvelles thérapies plus efficaces contre cette maladie. L’IRIC fonctionne selon un modèle unique au Canada. Sa façon innovante d’envisager la recherche a déjà permis de réaliser des découvertes qui auront, au cours des prochaines années, une incidence significative dans la lutte contre le cancer. Pour plus d’informations : www.iric.ca
Conseiller en communication et relations avec les médias
Institut de recherche en immunologie et en cancérologie│IRIC
Université de Montréal